Examples of using Compared with patients in English and their translations into Danish
{-}
-
Medicine
-
Colloquial
-
Official
-
Financial
-
Ecclesiastic
-
Official/political
-
Computer
D Renal impairment- Compared with patients with normal renal function creatinine clearance.
According to the manufacturers Tecfidera,the drug reduces the risk of recurrence in half compared with patients taking placebo.
Compared with patients who did not develop antibodies, no relationship between the presence of anti-panitumumab antibodies and pharmacokinetics, efficacy and safety has been observed.
However, there were no differences in the incidence of these adverse events compared with patients who received bone autograft, except in the case of osteomyelitis for which the incidence of osteomyelitis was statistically higher in the autograft group.
The incidence of serious infection was higher in Kineret-treated patients compared with patients receiving placebo 1.8% vs.
Renal impairment- Compared with patients with normal renal function(creatinine clearance> 80 ml/ min), plasma clearance is 1.2 to 1.4 times lower in patients with mild renal impairment(creatinine clearance 50 to 80 ml/ min) and on average 2 times lower in patients with moderate renal impairment creatinine clearance 30 to 50 ml/ min.
Antacid use was significantly less among patients in the lansoprazole groups compared with patients in the misoprostol and placebo groups.
Renal impairment- Compared with patients with normal renal function(creatinine clearance> 80 ml/ min) undergoing orthopaedic surgery and receiving fondaparinux 2.5 mg once daily, plasma clearance is 1.2 to 1.4 times lower in patients with mild renal impairment(creatinine clearance 50 to 80 ml/ min) and on average 2 times lower in patients with moderate renal impairment creatinine clearance 30 to 50 ml/ min.
Elevations in ALT were more common in psoriatic arthritis patients(PsA studies I- II) compared with patients in rheumatoid arthritis clinical studies.
The Committee for Medicinal Products for Human Use(CHMP) decided that for patients with MPS VI, treatment with Naglazyme provides benefits such as improved mobility when compared with patients given placebo.
The overall amount of cortisol absorbed into the blood was around 20% lower in patients taking Plenadren compared with patients taking conventional hydrocortisone treatment.
The dosing recommendations in patients with renal impairment, with increased dosing interval, are expected to result in higher peak plasma concentrations andlower Cmin levels in patients with renal impairment compared with patients with normal renal function.
A greater proportion of patients treated with lisinopril received additional frusemide(27%) compared with patients treated with nifedipine SR 17%; p=0.055.
Statistically significant improvements in HAQ-DI scores were observed in patients treated with RoActemra compared with patients treated with DMARDs.
American Cancer Society 2011 research study on fish oil and chemotherapy showed dramatically increased response rates andoverall survival time(compared with patients not taking fish oil) for NON-small cell lung cancer patients, April 2011 Newsletter, p. 15-17.
The Committee for Medicinal products for Human Use(CHMP) decided that in patients with wet AMD, 1 year of treatment with Macugen(0.3 mg or 1 mg)reduces vision loss when compared with patients given sham intervention.
Adult patients treated with Enbrel andanakinra were observed to have a higher rate of serious infection when compared with patients treated with either Enbrel or anakinra alone historical data.
In TRITON, for every 1000 patients treated with Efient, there were 22 fewer patients with myocardial infarction, and5 more with non- CABG-related TIMI major haemorrhages, compared with patients treated with clopidogrel.
In patients(n=3) with CLcrea between 20 and 40 ml/ min,the average CL/ F is reduced by 25% compared with patients with normal renal function.
During a randomised withdrawal period, significantly more patients re-randomised to placebo experienced disease relapse(loss of PASI 75 response) compared with patients re-randomised to Enbrel.
In the 12 week study involving peritoneal dialysis patients however,similar iPTH reductions were seen compared with patients receiving calcium acetate.
There was an increase in WHO Grade 3 or4 haematological toxicity in patients treated with the combination of Herceptin and paclitaxel compared with patients receiving paclitaxel alone 34% versus 21.
The plasma clearance of AsIII in patients with severe renal impairment(creatinine clearance less than 30 mL/ min)was 40% lower when compared with patients with normal renal function see section 4.4.
Disease activity outcomes In all three studies, rituximab 2 x 1000 mg significantly increased the proportion of patients achieving at least a 20% improvement in ACR score compared with patients treated with methotrexate alone Table 7.
An increase in the incidence of diarrhoea, primarily mild to moderate in severity,has also been observed in patients receiving Herceptin in combination with paclitaxel or docetaxel compared with patients receiving paclitaxel or docetaxel alone.
An increased incidence of infections, primarily mild upper respiratory infections of minor clinical significance or catheter infections,has been observed primarily in patients treated with Herceptin plus paclitaxel or docetaxel compared with patients receiving paclitaxel or docetaxel alone.
Although sufficient data are not available to adequately demonstrate the long term efficacy of ropinirole in Restless Legs Syndrome(see section 4.2), in a 36-week study,patients who continued on ropinirole demonstrated a significantly lower relapse rate compared with patients randomised to placebo 33% versus 58%, p=0.0156.
In the acute tibia fracture pivotal trial, InductOs increased the probability of fracture healing;patients treated with InductOs 1.5 mg/ml had a 44% reduced risk for treatment failure(secondary intervention to promote fracture healing) compared with patients in the standard-care group RR 0.56; 95% CI 0.40 to 0.78.
In placebo-controlled trials in elderly patients with dementia there was a significantly higher incidence(approximately 3-fold increased) of CVAEs, such as stroke(including fatalities) andtransient ischaemic attack in patients treated with RISPERDAL compared with patients treated with placebo mean age 85 years; range 73 to 97.